Eupraxia Pharmaceuticals (EPRXF) News Today → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free EPRXF Stock Alerts C$2.94 +0.17 (+6.14%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEQS-News: CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growthmarkets.businessinsider.com - April 27 at 5:03 PMEupraxia Pharmaceuticals Inc (EPRX-WT.TO)ca.finance.yahoo.com - April 20 at 9:54 AMEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024finance.yahoo.com - April 11 at 7:12 AMEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024prnewswire.com - April 11 at 7:00 AMEupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024finance.yahoo.com - April 3 at 8:02 PMEupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Resultsfinance.yahoo.com - April 1 at 5:58 PMEQS-News: APONTIS PHARMA expects profitable growth again in 2024markets.businessinsider.com - March 29 at 3:30 PMEupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Millionfinance.yahoo.com - March 15 at 11:45 AMEupraxia Pharma Shares Drop After Stock Offering Pricesmarketwatch.com - March 12 at 7:54 PMCanadian Investment Regulatory Organization Trade Resumption - EPRXfinance.yahoo.com - March 12 at 9:54 AMEupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Millionfinance.yahoo.com - March 12 at 9:54 AMEupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Millionfinance.yahoo.com - March 11 at 7:22 PMProfit Setback For Simcere Pharma In Novel Drugs Questseekingalpha.com - March 1 at 10:20 AMAnalysts Offer Insights on Healthcare Companies: Morphic Holding (MORF) and Vertex Pharmaceuticals (VRTX)markets.businessinsider.com - February 27 at 1:25 AMWest Pharmaceutical reports mixed Q4 results; initiates FY24 outlookmsn.com - February 15 at 8:53 AMMedical equipment maker West Pharmaceutical forecasts weak annual resultsreuters.com - February 15 at 8:53 AMVertex Pharmaceuticals 4Q Net, Revenue Beat Estimatesmarketwatch.com - February 6 at 2:04 AMEupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitisfinance.yahoo.com - February 5 at 9:04 PMEupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARfinance.yahoo.com - February 1 at 9:34 AMEupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Kneefinance.yahoo.com - January 30 at 8:09 AMEupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectusfinance.yahoo.com - January 8 at 8:45 PMLexicon Pharmaceuticals: Navigating The Competitive HFpEF Landscape (Rating Downgrade)seekingalpha.com - January 1 at 7:03 AMEupraxia Pharmaceuticals Inc Ordinary Shares EPRXmorningstar.com - December 16 at 1:33 PMEditas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Updatemarketwatch.com - December 13 at 12:25 PMStocks in play: Eupraxia Pharmaceuticals Inc.ca.finance.yahoo.com - December 12 at 4:08 PMEupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE Trialfinance.yahoo.com - December 12 at 9:46 AMEupraxia Pharmaceuticals Announces Clinical and Corporate Updatefinance.yahoo.com - December 11 at 8:14 AMVerrica Pharmaceuticals Reports Third Quarter 2023 Financial Resultsmarkets.businessinsider.com - November 9 at 9:29 AMMirum Pharmaceuticals earnings preview: what Wall Street is expectingmarkets.businessinsider.com - November 1 at 7:58 PMEupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatologyfinance.yahoo.com - November 1 at 9:58 AMDechra Pharmaceuticals rises Friday, outperforms marketmarketwatch.com - October 27 at 12:50 PMWest Pharma Cuts 2023 Sales View, Boosts Adjusted Earnings View, as Ordering Trends Changemarketwatch.com - October 26 at 10:16 AMClosing Bell: Eupraxia Pharmaceuticals Inc WT down on Wednesday (EPRX-WT)theglobeandmail.com - October 12 at 12:03 AMClosing Bell: Eupraxia Pharmaceuticals Inc WT down on Tuesday (EPRX-WT)theglobeandmail.com - October 11 at 2:02 PMEupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic Esophagitisfinance.yahoo.com - October 11 at 9:01 AMSyndax Pharma falls after early data for leukemia therapyseekingalpha.com - October 2 at 10:33 AMClosing Bell: Eupraxia Pharmaceuticals Inc down on Friday (EPRX)theglobeandmail.com - September 29 at 8:17 PMJefferies upgrades this pharma stock, citing overlooked 'blockbuster' drug opportunitiescnbc.com - September 25 at 8:02 AMDechra Pharmaceuticals rises Wednesday, still underperforms marketmarketwatch.com - September 20 at 2:19 PMDirexion Daily Pharmaceutical & Medical Bull 3X Shares declares quarterly distribution of $0.0353msn.com - September 20 at 2:19 PMEupraxia Pharmaceuticals Announces Change of Auditorfinance.yahoo.com - September 7 at 9:21 PMDechra Pharmaceuticals remains steady Thursday, underperforms marketmarketwatch.com - September 7 at 4:20 PMEupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023finance.yahoo.com - September 6 at 8:17 PMEupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 11 at 5:04 PMAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Myriad Genetics (MYGN)markets.businessinsider.com - August 7 at 6:54 AMEupraxia Pharmaceuticals Shares Climb With Plans for Private Placementmarketwatch.com - August 4 at 3:46 PMEupraxia Pharmaceuticals Announces a Non-Brokered Private Placement of up to C$22 Millionfinance.yahoo.com - August 4 at 7:09 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Syndax Pharmaceuticals (SNDX) and Kodiak Sciences (KOD)markets.businessinsider.com - July 25 at 3:41 AMAnalysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Ascendis Pharma (ASND)markets.businessinsider.com - July 18 at 7:39 AMEupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IARfinance.yahoo.com - June 26 at 8:07 AM Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRXF and its competitors with MarketBeat's FREE daily newsletter. Email Address The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about... Click here to see Louis' new video for yourself. EPRXF Media Mentions By Week EPRXF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPRXF News Sentiment▼0.000.42▲Average Medical News Sentiment EPRXF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPRXF Articles This Week▼11▲EPRXF Articles Average Week Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Artelo Biosciences News Ascletis Pharma News Awakn Life Sciences News AXIM Biotechnologies News BerGenBio ASA News BriaCell Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:EPRXF) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
